how long will semaglutide be on fda shortage list ends as sets deadline for compounders The Wild East of semaglutide

Diabetic neuropathy: cutting-edge research and future directions

Peptides for weight loss can be safe when used under the guidance of a healthcare professional and in accordance with proper dosing and administration protocols

Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)

Studies on intermittent fasting have been conducted on both animals and humans